ArticleJournal of clinical practice and research2024
Is Sortilin an Indicator of Subclinical Atherosclerosis in Patients with Psoriasis?
Article in Journal of clinical practice and research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Relationship between sortilin with ApoB/ApoA ratio in military personnel with arterial hypertension.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Atherosclerosis and related cardiovascular events are quite common in patients with psoriasis. We aimed to evaluate the role of serum sortilin as a potential marker for subclinical atherosclerosis in psoriasis patients. Materials and Methods: Serum levels of sortilin were measured by Enzyme-Linked Immunosorbent Assay (ELISA) in 33 psoriasis patients and 33 healthy controls. Waist circumference and body mass index were recorded for both groups; fasting plasma glucose (FPG), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), serum lipid levels, and sortilin levels were also measured. Carotid and femoral intima-media thicknesses (CIMT, FIMT) were measured by ultrasonography (USG). Additionally, demographic characteristics, Psoriasis Area and Severity Index (PASI), age of onset, total duration, and presence of nail involvement were documented for patients in the study. Results: The mean serum sortilin level was 6.20±3.11 ng/mL in the patient group and 7.82±4.97 ng/mL in the control group. No statistically significant difference was found between serum sortilin levels in both groups (p=0.729). There was no statistically significant relationship between serum sortilin levels and disease severity (p=0.597). The right and left CIMT values of the patients were significantly higher than those of the controls (p=0.012, p=0.020, respectively). There was no significant difference in FIMT values between the two groups. A statistically significant relationship was found between serum sortilin levels and right CIMT in patients (p=0.031). Conclusion: The positive correlation between the level of sortilin and right CIMT in our patient group supports the notion that sortilin may be an indicator of subclinical atherosclerosis in psoriasis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.